H-07

H-07: sourced facts only. name: "Among the nine compounds, H-07 emerged as the most balanced dual inhibitor, with proteasome IC50 = 4.2 nM and HDAC6 IC50 = 29.8 nM." [PMID:42594764]; target: "Among the nine compounds, H-07 emerged as the most balanced dual inhibitor, with proteasome IC50 = 4.2 nM and HDAC6 IC50 = 29.8 nM." [PMID:42594764]; developer: "Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou 310023, Zhejiang Province, China." [PMID:42594764]; stage: "In RPMI-8226 cells, H-07 increased ac-α-tubulin and ac-histone H3 levels and induced PARP cleavage-findings consistent with engagement of both HDAC6 and class I HDACs, in addition to the expected effects from proteasome inhibition." [PMID:42594764]